Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
1. Overall objective response rate was 30%, with 1 patient having a complete response. 2. Grade 3-4 treatment-related events occurred...
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
1. Invasive disease-free survival occurred in 19.7% of the T-DM1 group and 32.2% in the trastuzumab group, with an HR...
Neoadjuvant Nivolumab/Ipilimumab Vs Chemotherapy in Resectable NSCLC
1. Median event-free survival was 54.8 months with immunotherapy vs 20.9 months with chemotherapy, with HR 0.77 (non-significant). 2. Grade...
Radiofrequency Ablation vs Stereotactic Body Radiotherapy for Recurrent HCC
1. Local progression-free survival at 3 years was 84.3% in the SBRT group vs 67.3% in the RFA group, with...
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
1. Median progression-free survival was 9.4 months in the imlunestrant–abemaciclib group vs 5.5 months in the imlunestrant group with HR...
Fosrolapitant/Palonosetron in Chemotherapy-Induced Nausea and Vomiting
1. The complete response rate at the overall phase in cycle 1 was 77.7% vs 78.2% with treatment vs control...
Nivolumab plus Ipilimumab in MSI-High Metastatic Colorectal Cancer
1. Progression-free survival at 12 months was 79% with nivolumab/ipilimumab vs 21% with chemotherapy, and 24-month PFS was 72% and...
Early Ramucirumab/Paclitaxel vs Continuation of First-line Chemotherapy in Advanced HER2-negative Gastric/Gastroesophageal Cancer
1. Median PFS was 6.6 months in the switch maintenance group and 3.5 months in the control group with HR...
Radiotherapy with cetuximab or durvalumab for advanced HNSCC
1. The 2-year progression-free survival was 50.6% in the durvalumab group vs 63.7% in the cetuximab group with HR 1.33...
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
1. The median progression-free survival was 15.0 months in the inavolisib and 7.3 months in the placebo group, with HR...
